3.76 USD
▼-0.02-0.53%
盘后 3.74 0.00%
2026-09-16
市值
$20.21M
市盈率
—
EPS
-4.95
股息率
—
52 周区间
3.19 – 21.40
成交量
27.71K
Beta
—
目标价
—
52W 低 3.1952W 高 21.40
价格走势
公司简介
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for th...